|
Gene: HARS2 |
Gene summary for HARS2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | HARS2 | Gene ID | 23438 |
Gene name | histidyl-tRNA synthetase 2, mitochondrial | |
Gene Alias | HARSL | |
Cytomap | 5q31.3 | |
Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | P49590 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23438 | HARS2 | LZE4T | Human | Esophagus | ESCC | 1.71e-03 | 1.41e-01 | 0.0811 |
23438 | HARS2 | LZE8T | Human | Esophagus | ESCC | 3.40e-02 | 1.03e-01 | 0.067 |
23438 | HARS2 | LZE24T | Human | Esophagus | ESCC | 5.07e-08 | 2.57e-01 | 0.0596 |
23438 | HARS2 | P1T-E | Human | Esophagus | ESCC | 3.71e-04 | 2.89e-01 | 0.0875 |
23438 | HARS2 | P2T-E | Human | Esophagus | ESCC | 1.62e-08 | 2.42e-01 | 0.1177 |
23438 | HARS2 | P4T-E | Human | Esophagus | ESCC | 4.20e-09 | 2.44e-01 | 0.1323 |
23438 | HARS2 | P5T-E | Human | Esophagus | ESCC | 9.30e-11 | 2.08e-01 | 0.1327 |
23438 | HARS2 | P8T-E | Human | Esophagus | ESCC | 8.75e-09 | 1.51e-01 | 0.0889 |
23438 | HARS2 | P9T-E | Human | Esophagus | ESCC | 1.96e-04 | 2.06e-01 | 0.1131 |
23438 | HARS2 | P10T-E | Human | Esophagus | ESCC | 5.10e-07 | 1.13e-01 | 0.116 |
23438 | HARS2 | P11T-E | Human | Esophagus | ESCC | 3.11e-15 | 5.78e-01 | 0.1426 |
23438 | HARS2 | P12T-E | Human | Esophagus | ESCC | 4.57e-22 | 3.93e-01 | 0.1122 |
23438 | HARS2 | P15T-E | Human | Esophagus | ESCC | 1.03e-09 | 1.95e-01 | 0.1149 |
23438 | HARS2 | P16T-E | Human | Esophagus | ESCC | 3.44e-14 | 1.93e-01 | 0.1153 |
23438 | HARS2 | P17T-E | Human | Esophagus | ESCC | 2.19e-02 | 1.33e-01 | 0.1278 |
23438 | HARS2 | P20T-E | Human | Esophagus | ESCC | 7.32e-19 | 4.92e-01 | 0.1124 |
23438 | HARS2 | P21T-E | Human | Esophagus | ESCC | 3.44e-11 | 2.49e-01 | 0.1617 |
23438 | HARS2 | P22T-E | Human | Esophagus | ESCC | 1.71e-18 | 3.52e-01 | 0.1236 |
23438 | HARS2 | P23T-E | Human | Esophagus | ESCC | 1.00e-07 | 2.42e-01 | 0.108 |
23438 | HARS2 | P24T-E | Human | Esophagus | ESCC | 1.42e-08 | 1.92e-01 | 0.1287 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
GO:00063992 | Esophagus | ESCC | tRNA metabolic process | 122/8552 | 179/18723 | 9.03e-10 | 2.19e-08 | 122 |
GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
GO:00063991 | Oral cavity | OSCC | tRNA metabolic process | 101/7305 | 179/18723 | 1.65e-06 | 2.15e-05 | 101 |
GO:00346608 | Thyroid | PTC | ncRNA metabolic process | 239/5968 | 485/18723 | 5.54e-16 | 4.26e-14 | 239 |
GO:003466021 | Thyroid | ATC | ncRNA metabolic process | 240/6293 | 485/18723 | 2.03e-13 | 9.91e-12 | 240 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HARS2 | SNV | Missense_Mutation | novel | c.619N>T | p.Asp207Tyr | p.D207Y | P49590 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HARS2 | SNV | Missense_Mutation | novel | c.1199C>T | p.Thr400Ile | p.T400I | P49590 | protein_coding | tolerated(0.09) | benign(0) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HARS2 | SNV | Missense_Mutation | novel | c.1278N>T | p.Leu426Phe | p.L426F | P49590 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HARS2 | SNV | Missense_Mutation | c.1480N>C | p.Asn494His | p.N494H | P49590 | protein_coding | tolerated(0.15) | benign(0.005) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
HARS2 | SNV | Missense_Mutation | novel | c.1094N>G | p.Asp365Gly | p.D365G | P49590 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
HARS2 | SNV | Missense_Mutation | novel | c.688N>G | p.Ser230Gly | p.S230G | P49590 | protein_coding | tolerated(0.07) | benign(0.029) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
HARS2 | SNV | Missense_Mutation | novel | c.1451G>A | p.Ser484Asn | p.S484N | P49590 | protein_coding | tolerated(0.09) | possibly_damaging(0.555) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HARS2 | SNV | Missense_Mutation | novel | c.1019N>C | p.Val340Ala | p.V340A | P49590 | protein_coding | deleterious(0) | possibly_damaging(0.744) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
HARS2 | SNV | Missense_Mutation | c.394N>A | p.Leu132Ile | p.L132I | P49590 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-BG-A0M4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
HARS2 | SNV | Missense_Mutation | c.153G>T | p.Glu51Asp | p.E51D | P49590 | protein_coding | tolerated(0.43) | benign(0.071) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |